Advertisement

The Scientist

» FDA, immunology and ecology

Most Recent

image: Climate Change Speeds Extinctions

Climate Change Speeds Extinctions

By | May 3, 2015

Species die-offs are expected to accelerate as greenhouse gases accumulate, according to a meta-analysis.

0 Comments

image: Filippos Porichis: Immunoregulator

Filippos Porichis: Immunoregulator

By | May 1, 2015

Principal Investigator, Ragon Institute of MGH, MIT, and Harvard. Age: 33

0 Comments

image: Llamas as Lab Rats

Llamas as Lab Rats

By | May 1, 2015

From diagnostics to vaccines, llama antibodies point to new directions in HIV research.

0 Comments

image: Looking for Latent HIV

Looking for Latent HIV

By | May 1, 2015

Sequencing HIV integration sites suggests that clonally expanded T-cell populations may not be the main source of latent virus.

0 Comments

image: Soluble Signal

Soluble Signal

By | May 1, 2015

An immune protein previously thought to mark inactive T cells has a free-floating form that correlates with HIV disease progression.

0 Comments

image: Defeating the Virus

Defeating the Virus

By | May 1, 2015

Recent discoveries are spurring a renaissance in HIV vaccine research and development.

0 Comments

image: Bees Drawn to Pesticides

Bees Drawn to Pesticides

By | April 24, 2015

One study shows the insects prefer food laced with pesticides, while another adds to the evidence that the chemicals are harmful to some pollinators.

0 Comments

image: FDA Calls for Data on ALS Drug

FDA Calls for Data on ALS Drug

By | April 21, 2015

In the midst of a debate about an experimental drug’s early approval, the US Food and Drug Administration requests that full trial results be released.

0 Comments

image: Protein Spurs T-Cell Proliferation

Protein Spurs T-Cell Proliferation

By | April 17, 2015

A newly discovered protein promotes immunity to viruses and cancer by triggering the production of cytotoxic T cells.

1 Comment

image: ALS Drug Access Debated

ALS Drug Access Debated

By | April 7, 2015

Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.

2 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
LI-COR
LI-COR

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
The Scientist
The Scientist